Wong (now at Stanford University) figured the mutated gene might make an ideal target for a vaccine, as it creates an abnormalprotein not seen in healthy cells.
Benlysta is delivered directly into a vein (intravenous infusion) and is the first inhibitor designed to target B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells thought to be a problem in lupus.
Parkinson's disease is characterized by clumps of abnormal brain proteins called Lewy bodies of which a-synuclein (a-syn) protein is the principal component.